The human protooncogene c-erbB2, also known as HER-2/neu is sited on 17q21 chromosome and codifies a transmembranous glycoprotein of 185 KD, named c-erbB2 protein, with tyrosin-kinasic activity and homologue from molecular point of view with the epidermal growth factor receptor (EGFR). In order to detect the tissular expression of c-erbB2 protein, tissular samples from 10 patients with primary endometrial cancer were immmunohistochemically processed. C-erbB2 immunostaining using c-erbB2 (21N) antiserum marked the cellular membranes and, occasionally, the cytoplasma of the tumoral cells. The overexpression of c-erbB2 protein in the examed cases was correlated with the clinical status, histological type of the tumour and the differentiation degree. All the patients presented immunoreactivity of variable intensity for c-erbB2 protein. The alterations of c-erbB2 protein are considered to be an unfavourable prognostic factor implied in the tumoral progression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions.
Medicina (Kaunas)
December 2024
5th Department of Oncology, Metropolitan General Hospital, 155 62 Athens, Greece.
The most common histological subtypes of endometrial cancer consist of endometrioid and uterine serous carcinoma, with the latter being more aggressive and accompanied by poor prognosis. Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor associated with cell proliferation, differentiation, and survival. HER2 positivity can be diagnosed in many solid tumors.
View Article and Find Full Text PDFComparison of molecular analysis results determined by next-generation sequencing to immunohistochemical indicators and clinicopathological parameters in prostate adenocarcinomas.
Indian J Pathol Microbiol
April 2024
Department of Pathology, Aydın Adnan Menderes University, Aydın, Turkey.
Background: Prostate cancer is a common cancer in males, frequently leading to mortality. Multiple genetic factors play roles in prostate cancer pathogenesis. Demonstration of pathological pathways and customised treatment options have been possible with next-generation sequencing.
View Article and Find Full Text PDFHER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.
Cancers (Basel)
August 2023
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, LSOG 305, P.O. Box 208063, New Haven, CT 06520, USA.
Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are two rare histologic variants of uterine carcinoma, with distinct molecular profiles and aggressive metastatic potential. As the effectivity of traditional platinum-based chemotherapy for USC and UCS is low, and there are high rates of resistance and recurrence, the development of novel targeted therapeutics is needed. Human epidermal growth factor receptor 2 (HER2) has proven to be an oncogene of increasing interest in these cancers, as HER2 protein overexpression and/or c- gene amplification ranges from ~30 to 35% in USC, and between ~15 and 20% in UCS.
View Article and Find Full Text PDFDetection of human papilloma virus in breast cancer biopsies using PCR and immunohistochemistry at the santa rosa hospital during 2019.
Rev Peru Med Exp Salud Publica
March 2023
3 Departamento de Patología clínica y Anatomía Patológica, Hospital Santa Rosa, Lima, Perú.
Objectives.: Motivation for the study: there are few studies about high-risk Human Papillomavirus in patients with breast cancer, which is currently the most recurrent neoplasm in Peru. Main findings: greater presence of Human Papillomavirus was evidenced in infiltrating ductal carcinoma and grade III samples.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!